Cost-effectiveness analysis of continuous subcutaneous insulin infusion versus multiple daily insulin for treatment of children with type 1 diabetes

Zhang, Lijuan; Leng, Xuefei; Tian, Fei; Xiao, Dong; Xuan, Jianwei; Yang, Hongxiu; Liu, Jing; Chen, Zhihong

doi:10.1080/00325481.2022.2088938

Cited by 1 publication

(2 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The benefits of CSII for longterm glycemic management need to be validated by additional studies in clinical practice. A number of Chinese scholars who concentrated on T1DM patients demonstrated that utilization of insulin pumps is associated with a lower level of HbA1c (12,(24)(25)(26). Further cost-effectiveness analysis of CSII therapy vs. MDI therapy also suggested that CSII therapy should be considered as a preferred alternative to MDI therapy for Chinese T1DM patients (12,26).…”

Section: Discussionmentioning

confidence: 99%

“…A number of Chinese scholars who concentrated on T1DM patients demonstrated that utilization of insulin pumps is associated with a lower level of HbA1c (12,(24)(25)(26). Further cost-effectiveness analysis of CSII therapy vs. MDI therapy also suggested that CSII therapy should be considered as a preferred alternative to MDI therapy for Chinese T1DM patients (12,26). Our results provided further evidence that CSII therapy is effective for management of Chinese T1DM patients, which was confirmed by a lower HbA1c level and better CGM-derived metrics.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Comparing the effectiveness of continuous subcutaneous insulin infusion with multiple daily insulin injection for patients with type 1 diabetes mellitus evaluated by retrospective continuous glucose monitoring: A real-world data analysis

Guo

Zhang

et al. 2022

Front. Public Health

View full text Add to dashboard Cite

ObjectiveRegarding the effects and practical application of insulin pumps on patients with type 1 diabetes mellitus (T1DM), the real-world evidence is limited especially concerning the incidence of hypoglycemia. This study aimed to compare the efficacy of continuous subcutaneous insulin infusion (CSII) therapy with multiple daily injection (MDI) therapy on glycemic metrics evaluated by retrospective continuous glucose monitoring (CGM) in Chinese patients with T1DM.MethodsIn total, 362 T1DM Chinese patients from the outpatient department of the Second Xiangya Hospital, Central South University, who underwent intensive insulin therapy and used a retrospective CGM system were included in this retrospective cross-sectional study. Comprehensive analysis of clinical and biological features and retrospective CGM derived-metrics was performed on the 362 enrolled T1DM patients who underwent CSII (n = 61) or MDI (n = 301) therapy (defined as 4 or more insulin injections per day).ResultsOur findings demonstrated that patients who underwent CSII therapy, compared with those who received MDI therapy, had lower levels of hemoglobin A1c (HbA1c) and fasting blood glucose; moreover, CSII therapy was associated with better glycemic outcomes in terms of increasing time in range (TIR), decreasing time above range (TAR), and achieving CGM-associated targets of TIR ≥70% and TAR <25%. However, patients who underwent CSII therapy did not experience decreasing time below range (TBR), achieving CGM-associated targets of TBR <4%, and reduction of the risk of hypoglycemia as evidenced by comparing TBR and low blood glucose index (LBGI) between the two treatment regimens. The parameters of glycemic variability, such as standard deviation of glucose (SD), mean amplitude glycemic excursion (MAGE), and large amplitude glycemic excursion (LAGE) in T1DM patients who underwent CSII therapy outperformed.ConclusionOur results provided further evidence that CSII therapy is safe and effective for management of Chinese T1DM patients, which was confirmed by a lower HbA1c level and better CGM-derived metrics but no demonstration of improvment in the risk of hypoglycemia. To achieve more satisfactory glycemic outcomes through the utilization of CSII therapy for Chinese T1DM patients, a strong physician-patient relationship is essential.

show abstract